MODIFY — Sponsor: GSK — Drug: depemokimab — At-risk Type 2 asthma — Phase 3b/4

PERSIST ASTHMA-2 — Sponsor: GSK — Drug: GSK5784283 (felcorekibart) — Uncontrolled asthma, adults and adolescents — Phase 3